We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
Read MoreHide Full Article
Key Takeaways
Vertex's BLA for povetacicept in adults with IgAN has been accepted by the FDA.
The FDA is expected to make a decision on the application for povetacicept by Nov. 30, 2026.
If approved, VRTX plans to launch povetacicept as a once-every-four-weeks at-home auto-injector.
Vertex Pharmaceuticals (VRTX - Free Report) announced that the FDA has accepted its biologics license application (BLA) seeking approval for its investigational candidate, povetacicept, for treating adults with immunoglobulin A nephropathy (IgAN), a rare progressive kidney disease.
With the FDA accepting the BLA, a decision from the regulatory body is expected on Nov 30, 2026.
If approved, povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) cytokines, will become the first commercialized therapy in Vertex’s emerging nephrology franchise.
The company plans to launch povetacicept in a low-volume (<0.5 mL) subcutaneous auto-injector delivered once every four weeks via at-home administration, upon potential approval.
Year to date, shares of Vertex have lost 3.3% against the industry’s rise of 0.7%.
Image Source: Zacks Investment Research
VRTX’s Recent Development Activities With Povetacicept
Based on positive interim data from the RAINIER phase III study in IgAN, a rolling BLA filing for povetacicept for IgAN was completed in March 2026. Data from the RAINIER study showed that povetacicept led to a rapid, deep and sustained improvement in proteinuria (excess protein in the urine), a direct consequence of IgAN.
Vertex believes povetacicept has pipeline-in-a-product potential for B-cell-mediated diseases. Povetacicept is designed to target two proteins, namely BAFF and APRIL, which are jointly responsible for the cause of multiple serious autoimmune diseases.
Vertex is also conducting a pivotal phase II/III study of povetacicept for a second potential renal indication, primary membranous nephropathy (pMN). Vertex has also initiated a phase II study on povetacicept for treating generalized myasthenia gravis (gMG) in the first half of 2026.
Povetacicept was added to Vertex’s portfolio following the acquisition of Alpine in 2024. Vertex believes povetacicept holds significant commercial opportunities.
Growing Competition in the Targeted Space
Upon potential approval, povetacicept is likely to face competition from the likes of Calliditas Therapeutics’ Tarpeyo, Novartis’ (NVS - Free Report) Fabhalta and Travere Therapeutics’ (TVTX - Free Report) Filspari.
Novartis’ Fabhalta is approved under the accelerated pathway for reducing proteinuria in adults with primary IgAN at risk of rapid disease progression. The NVS drug is also approved for complement 3 glomerulopathy and paroxysmal nocturnal hemoglobinuria indications.
Both Calliditas’ Tarpeyo and Travere’s Filspari are approved for a similar indication — to slow the decline in kidney function in adults with primary IgAN who are at risk of disease progression.
View the Zacks #1 Rank List
Image: Bigstock
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
Key Takeaways
Vertex Pharmaceuticals (VRTX - Free Report) announced that the FDA has accepted its biologics license application (BLA) seeking approval for its investigational candidate, povetacicept, for treating adults with immunoglobulin A nephropathy (IgAN), a rare progressive kidney disease.
With the FDA accepting the BLA, a decision from the regulatory body is expected on Nov 30, 2026.
If approved, povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) cytokines, will become the first commercialized therapy in Vertex’s emerging nephrology franchise.
The company plans to launch povetacicept in a low-volume (<0.5 mL) subcutaneous auto-injector delivered once every four weeks via at-home administration, upon potential approval.
Year to date, shares of Vertex have lost 3.3% against the industry’s rise of 0.7%.
Image Source: Zacks Investment Research
VRTX’s Recent Development Activities With Povetacicept
Based on positive interim data from the RAINIER phase III study in IgAN, a rolling BLA filing for povetacicept for IgAN was completed in March 2026. Data from the RAINIER study showed that povetacicept led to a rapid, deep and sustained improvement in proteinuria (excess protein in the urine), a direct consequence of IgAN.
Vertex believes povetacicept has pipeline-in-a-product potential for B-cell-mediated diseases. Povetacicept is designed to target two proteins, namely BAFF and APRIL, which are jointly responsible for the cause of multiple serious autoimmune diseases.
Vertex is also conducting a pivotal phase II/III study of povetacicept for a second potential renal indication, primary membranous nephropathy (pMN). Vertex has also initiated a phase II study on povetacicept for treating generalized myasthenia gravis (gMG) in the first half of 2026.
Povetacicept was added to Vertex’s portfolio following the acquisition of Alpine in 2024. Vertex believes povetacicept holds significant commercial opportunities.
Growing Competition in the Targeted Space
Upon potential approval, povetacicept is likely to face competition from the likes of Calliditas Therapeutics’ Tarpeyo, Novartis’ (NVS - Free Report) Fabhalta and Travere Therapeutics’ (TVTX - Free Report) Filspari.
Novartis’ Fabhalta is approved under the accelerated pathway for reducing proteinuria in adults with primary IgAN at risk of rapid disease progression. The NVS drug is also approved for complement 3 glomerulopathy and paroxysmal nocturnal hemoglobinuria indications.
Both Calliditas’ Tarpeyo and Travere’s Filspari are approved for a similar indication — to slow the decline in kidney function in adults with primary IgAN who are at risk of disease progression.
VRTX’s Zacks Rank
Vertex currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.